Highest R&D Intensity in Health Care
Health Care sector companies ranked by r&d intensity. Companies ranked by R&D spending as a percentage of revenue, indicating focus on innovation and future growth.
Health Care SectorTop 50 by R&D Intensity
| # | Company | R&D Intensity |
|---|---|---|
| 1 | INCYIncyte | 39.9% |
| 2 | BFLYButterfly Network, Inc. | 37.1% |
| 3 | TXG10x Genomics, Inc. | 37.1% |
| 4 | GHGuardant Health, Inc. | 37.1% |
| 5 | HTFLHeartflow, Inc. | 36.9% |
| 6 | MIRMMirum Pharmaceuticals, Inc. | 35.7% |
| 7 | EXELExelixis | 35.6% |
| 8 | ALNYALNYLAM PHARMACEUTICALS, INC. | 35.5% |
| 9 | NBIXNeurocrine Biosciences | 35.5% |
| 10 | TBPHTheravance Biopharma, Inc. | 34.8% |
| 11 | BBNXBeta Bionics, Inc. | 34.7% |
| 12 | NVCRNovoCure Ltd | 34.3% |
| 13 | ADPTAdaptive Biotechnologies Corp | 33.9% |
| 14 | CORTCorcept Therapeutics Incorporated | 33.5% |
| 15 | VRTXVertex Pharmaceuticals | 32.6% |
| 16 | IRWDIRONWOOD PHARMACEUTICALS INC | 32.1% |
| 17 | ACADAcadia Pharmaceuticals | 30.7% |
| 18 | NVAXNOVAVAX INC | 30.5% |
| 19 | LGNDLigand Pharmaceuticals, Inc. | 30.3% |
| 20 | GKOSGlaukos Corp. | 29.7% |
| 21 | APLSApellis Pharmaceuticals, Inc. | 29.5% |
| 22 | AXSMAxsome Therapeutics, Inc. | 28.7% |
| 23 | BMRNBioMarin Pharmaceutical | 28.6% |
| 24 | SYKStryker Corporation | 27.7% |
| 25 | NTRANatera, Inc. | 27.1% |
| 26 | PTCTPTC Therapeutics, Inc. | 26.3% |
| 27 | TGTXTG Therapeutics, Inc. | 26.0% |
| 28 | LQDALiquidia Corp | 24.8% |
| 29 | MRKMerck & Co. | 24.3% |
| 30 | PRCTPROCEPT BioRobotics Corp | 23.1% |
| 31 | ILMNIllumina, Inc. | 22.3% |
| 32 | DVAXDynavax Technologies Corp. | 22.2% |
| 33 | ALKSAlkermes plc | 22.0% |
| 34 | HQYHealthEquity | 21.9% |
| 35 | HRMYHarmony Biosciences Holdings, Inc. | 21.8% |
| 36 | CBLLCeribell, Inc. | 21.5% |
| 37 | FOLDAMICUS THERAPEUTICS, INC. | 21.4% |
| 38 | BMYBristol Myers Squibb | 20.6% |
| 39 | ARQTArcutis Biotherapeutics, Inc. | 20.5% |
| 40 | LLYLilly (Eli) | 20.5% |
| 41 | OPKOPKO HEALTH, INC. | 20.4% |
| 42 | AMGNAmgen | 19.8% |
| 43 | GILDGilead Sciences | 19.7% |
| 44 | TNDMTandem Diabetes Care | 19.0% |
| 45 | MNKDMANNKIND CORP | 19.0% |
| 46 | RPRXRoyalty Pharma plc | 19.0% |
| 47 | CDNACareDx, Inc. | 18.8% |
| 48 | PHATPhathom Pharmaceuticals, Inc. | 18.7% |
| 49 | ATRCAtriCure, Inc. | 18.6% |
| 50 | JAZZJazz Pharmaceuticals | 18.3% |
Understanding R&D Intensity
R&D intensity measures how much a company invests in research and development relative to its revenue. Higher R&D intensity often indicates a focus on innovation and long-term competitive advantage. Tech companies like Intel and Qualcomm typically have 15-25% R&D intensity, while pharmaceutical companies invest 10-20%.
Rankings are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from this ranking.
Related Rankings
Same Sector
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.